Maximum quantity allowed is 999
请选择数量
CAS RN: 2207-75-2 | 产品编码: O0164
Potassium Oxonate
×
![]()
×
技术规格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
物性（参考值）
| 熔点 | 300 °C |
GHS
相关法规
| RTECS# | RR4580000 |
运输信息
| HS编码* | 2933.69-000 |
应用
Potassium Oxonate: An Inhibitor of Orotate Phosphoribosyltransferase (OPRT)
Potassium oxonate is an inhibitor of orotate phosphoribosyltransferase (OPRT) that is an enzyme involved in the biosynthesis of pyrimidine nucleotides and catalyzes the phosphorylation of 5-FU [F0151] to an active metabolite 5-fluorouridine-5'-monophosphate (FUMP). The gastrointestinal toxicity (GIT) of the oral administration of 5-FU is also caused by the phosphorylation by OPRT in the gut wall. Potassium oxonate selectively and competitively inhibits OPRT. As a result, 5-FU associated gastrointestinal toxic effects are reduced. Potassium oxonate is often used as combined agents to enhance the antitumor activity of fluoropyrimidines, such as S-1 (tegafur [F0635] a prodrug of 5-FU, gimeracil [C2243] and potassium oxonate at a molar ratio of 1:0.4:1). (The product is for research purpose only.)
References
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
- Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats
- Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats
- Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats
- Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil
应用
Reagent for hyperuricemia (gout) model
References
- Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents
- Hyperuricemia induced by some antihypertensives and uricosuric drugs in oxonate-treated rats
- Y. Yonetani, M. Ishii, K. Iwaki, Jpn. J. Pharmacol. 1980, 30, 829.
- Use of the uricase-inhibited rat as an animal model in toxicology
- Beneficial effect of rutin on oxonate-induced hyperuricemia and renal dysfunction in mice
参考文献
TCIMail
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。